DB Alex Brown Boosts Guidant to 'Strong Buy'

Analyst Sheryl Zimmer says the drug maker's stent development deal puts it just behind Johnson & Johnson

DB Alex Brown upgraded Guidant Corp. (GDT ) to strong buy from buy.

Analyst Sheryl Zimmer says the agreement gives Guidant the ability to sell a paclitaxel coated Penta stent. She sees this ingenious (though unusual) agreement as an important positive as it meaningfully accelerates Guidant's drug-coated stent development -- putting them only six months behind Johnson & Johnson.

Zimmer says this news, coupled with recent positive developments for its Ancure AAA stent graft, indicates Guidant may finally be getting themselves back on a growth trajectory. She has a $42 target.

Before it's here, it's on the Bloomberg Terminal.